Penumbra Inc Q3 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Congrats on a great quarter. Maybe to start, Adam, you spoke about a lot of different new product launches, Lightning 7, some of the RED products. You talked about China and some of the adoption there. How do we think about the impact it had to sales in the quarter and what you're expecting, let's say, over the next 6 to 12 months? Also, throw in coronary. You don't break out products or the different sub-line items for those businesses. So how do we think about where we're seeing the biggest incremental dollar growth?

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Great. And maybe a quick follow-up. It's been a while since we got some -- you used to give out details on how many procedures you thought were happening in the U.S. and outside the U.S. neurothrombectomy markets. Do have any sense of maybe where the U.S. and Europe is on track for procedures this year? And if there's any way to gauge how -- just the business performance in those markets have been since the recall last year would be really helpful.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : All right. And if I could squeeze in one quick one. China, I know that used to be all a -- or predominantly a Medtronic market. Any sense of the impact you're making there? Is it still real early days? Or how do we think about the impact you're seeing?